These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7796291)

  • 1. Computer modeling of prostate cancer treatment. A paradigm for oncologic management?
    Miles BJ; Kattan MW
    Surg Oncol Clin N Am; 1995 Apr; 4(2):361-72. PubMed ID: 7796291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel computer based expert decision making model for prostate cancer disease management.
    Richman MB; Forman EH; Bayazit Y; Einstein DB; Resnick MI; Stovsky MD
    J Urol; 2005 Dec; 174(6):2310-8. PubMed ID: 16280831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical informatics and clinical decision making: the science and the pragmatics.
    Shortliffe EH
    Med Decis Making; 1991; 11(4 Suppl):S2-14. PubMed ID: 1837576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life after therapy for localized prostate cancer.
    Penson DF
    Cancer J; 2007; 13(5):318-26. PubMed ID: 17921731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive modeling in prostate cancer. Conclusions and reflections.
    Denis LJ; Gospodarowicz MK
    Cancer; 2009 Jul; 115(13 Suppl):3160-2. PubMed ID: 19544535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
    Adolfsson J
    Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.
    Elkin EB; Cowen ME; Cahill D; Steffel M; Kattan MW
    Med Decis Making; 2004; 24(5):504-10. PubMed ID: 15358999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    Dahm P; Yeung LL; Chang SS; Cookson MS
    J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision analysis of alternative treatment strategies for clinically localized prostate cancer.
    Walsh PC
    J Urol; 1993 Oct; 150(4):1330-2. PubMed ID: 8371423
    [No Abstract]   [Full Text] [Related]  

  • 14. Computerized utility assessment for cancer decision making: promises and pitfalls.
    Saigal CS
    Cancer Invest; 2009 Nov; 27(9):937-41. PubMed ID: 19832042
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer and urinary incontinence.
    Parsons BA; Evans S; Wright MP
    Maturitas; 2009 Aug; 63(4):323-8. PubMed ID: 19615834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling human behaviors and reactions under dangerous environment.
    Kang J; Wright DK; Qin SF; Zhao Y
    Biomed Sci Instrum; 2005; 41():265-70. PubMed ID: 15850116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment.
    Strigari L; Orlandini LC; Andriani I; d'Angelo A; Stefanacci M; Di Nallo AM; Benassi M
    Phys Med Biol; 2008 Sep; 53(18):5045-59. PubMed ID: 18723926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer: a chronic illness.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2007 Dec; 11(6):857-61. PubMed ID: 18063544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of quality of life in men with prostate cancer.
    Albaugh J; Hacker ED
    Clin J Oncol Nurs; 2008 Feb; 12(1):81-6. PubMed ID: 18258577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.